N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.924 NOK 3.69% Market Closed
Market Cap: 954.8m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Investor Relations

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Michael Thyring Engsig
Chief Executive Officer
No Bio Available
Mr. Harald Gurvin
Chief Financial Officer
No Bio Available
Mr. Ulrich Blaschke
Chief Technology Officer
No Bio Available
Dr. Agnete B. Fredriksen Ph.D.
Chief Scientific Officer & Business Development
No Bio Available
Ms. Louise Stubbe
Chief Legal Officer
No Bio Available
Dr. Klaus Edvardsen M.D., Ph.D.
Chief Research & Development Officer
No Bio Available

Contacts

Address
OSLO
Oslo
Oslo Science Park, Gaustadalleen 21
Contacts
+4722958193
nykode.com